Overview Dividends

(HSIC) Henry Schein - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8064071025

Dental Supplies, Medical Supplies, Equipment, Software, Services

Health Care Distributors
Market Cap in USD: 9,270m

IPO / Inception: 1995-11-03
Return 12m vs S&P 500: -6.89%

EPS (Earnings per Share)

EPS CAGR: -48.26%
EPS Trend: -38.1%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 0.07%
Rev. Trend: 17.9%

Last SUE: 1.54
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	25.0%
Value at Risk 5%th	38.9%
Relative Tail Risk	-5.61%

Reward TTM
Sharpe Ratio	0.45
Alpha	1.73
CAGR/Max DD	-0.02

Character TTM
Hurst Exponent	0.393
Beta	0.558
Beta Downside	0.389

Drawdowns 3y
Max DD	30.52%
Mean DD	17.95%
Median DD	18.18%

Description: HSIC Henry Schein January 07, 2026

Henry Schein Inc. (NASDAQ: HSIC) distributes a broad portfolio of health-care products and services to office-based dental and medical practices, laboratories, ambulatory surgery centers, and government or institutional clinics worldwide. Its operations are organized into three segments: Global Distribution & Value-Added Services, Global Specialty Products, and Global Technology, covering everything from dental consumables and equipment to pharmaceuticals, vaccines, and practice-management software.

According to the company’s FY 2023 filing, HSIC generated ≈ $9.1 billion in revenue, with a 6.4 % operating margin and adjusted EPS of $5.23. The firm reported a 5-year compounded annual revenue growth rate of roughly 8 %, driven by strong demand for digital dentistry tools and recurring consumable sales. Cash flow from operations exceeded $1.2 billion, supporting its non-recourse financing program for practitioner loans.

Key macro-drivers for HSIC include the aging U.S. and global populations, which raise demand for dental and orthopedic procedures, and the continued shift toward high-margin digital and implant-based treatments. Additionally, the broader health-care distribution sector benefits from consolidation trends and the need for integrated supply-chain solutions, which favor large, diversified distributors like Henry Schein.

For a deeper quantitative analysis, you might explore ValueRay’s platform, which aggregates real-time financial metrics and peer comparisons for HSIC and its industry peers.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (391.0m TTM) > 0 and > 6% of Revenue (6% = 776.3m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -0.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 9.63% (prev 9.74%; Δ -0.11pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 535.0m > Net Income 391.0m (YES >=105%, WARN >=100%)

Net Debt (3.31b) to EBITDA (980.0m) ratio: 3.37 <= 3.0 (WARN <= 3.5)

Current Ratio 1.40 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (121.0m) change vs 12m ago -4.74% (target <= -2.0% for YES)

Gross Margin 29.20% (prev 29.62%; Δ -0.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 119.2% (prev 117.9%; Δ 1.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 4.62 (EBITDA TTM 980.0m / Interest Expense TTM 146.0m) >= 6 (WARN >= 3)

Altman Z'' 2.68

(A) 0.11 = (Total Current Assets 4.39b - Total Current Liabilities 3.15b) / Total Assets 11.10b

(B) 0.30 = Retained Earnings (Balance) 3.38b / Total Assets 11.10b

(D) 0.51 = Book Value of Equity 3.15b / Total Liabilities 6.20b

Total Rating: 2.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 55.02

1. Piotroski 4.50pt

2. FCF Yield 3.04%

3. FCF Margin 2.95%

4. Debt/Equity 1.02

5. Debt/Ebitda 3.37

6. ROIC - WACC (= 2.45)%

7. RoE 11.58%

8. Rev. Trend 17.92%

9. EPS Trend -38.09%

What is the price of HSIC shares?

As of January 07, 2026, the stock is trading at USD 78.55 with a total of 1,570,734 shares traded.
Over the past week, the price has changed by +2.76%, over one month by +7.81%, over three months by +18.94% and over the past year by +9.46%.

Is HSIC a buy, sell or hold?

Henry Schein has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold HSIC.

Strong Buy: 3
Buy: 4
Hold: 8
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the HSIC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	77.6	-1.2%
Analysts Target Price	77.6	-1.2%
ValueRay Target Price	84.9	8.1%

HSIC Fundamental Data Overview January 01, 2026

Market Cap USD = 9.27b (9.27b USD * 1.0 USD.USD)
P/E Trailing = 24.1136
P/E Forward = 14.5985
P/S = 0.7165
P/B = 2.6774
P/EG = 1.7167
Beta = 0.888
Revenue TTM = 12.94b USD
EBIT TTM = 675.0m USD
EBITDA TTM = 980.0m USD
Long Term Debt = 2.15b USD (from longTermDebt, last quarter)
Short Term Debt = 1.02b USD (from shortTermDebt, last quarter)
Debt = 3.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.31b USD (from netDebt column, last quarter)
Enterprise Value = 12.57b USD (9.27b + Debt 3.44b - CCE 136.0m)
Interest Coverage Ratio = 4.62 (Ebit TTM 675.0m / Interest Expense TTM 146.0m)
FCF Yield = 3.04% (FCF TTM 382.0m / Enterprise Value 12.57b)
FCF Margin = 2.95% (FCF TTM 382.0m / Revenue TTM 12.94b)
Net Margin = 3.02% (Net Income TTM 391.0m / Revenue TTM 12.94b)
Gross Margin = 29.20% ((Revenue TTM 12.94b - Cost of Revenue TTM 9.16b) / Revenue TTM)
Gross Margin QoQ = 28.69% (prev 29.38%)
Tobins Q-Ratio = 1.13 (Enterprise Value 12.57b / Total Assets 11.10b)
Interest Expense / Debt = 1.10% (Interest Expense 38.0m / Debt 3.44b)
Taxrate = 20.44% (28.0m / 137.0m)
NOPAT = 537.0m (EBIT 675.0m * (1 - 20.44%))
Current Ratio = 1.40 (Total Current Assets 4.39b / Total Current Liabilities 3.15b)
Debt / Equity = 1.02 (Debt 3.44b / totalStockholderEquity, last quarter 3.36b)
Debt / EBITDA = 3.37 (Net Debt 3.31b / EBITDA 980.0m)
Debt / FCF = 8.65 (Net Debt 3.31b / FCF TTM 382.0m)
Total Stockholder Equity = 3.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.52% (Net Income 391.0m / Total Assets 11.10b)
RoE = 11.58% (Net Income TTM 391.0m / Total Stockholder Equity 3.38b)
RoCE = 12.21% (EBIT 675.0m / Capital Employed (Equity 3.38b + L.T.Debt 2.15b))
RoIC = 8.58% (NOPAT 537.0m / Invested Capital 6.26b)
WACC = 6.12% (E(9.27b)/V(12.71b) * Re(8.07%) + D(3.44b)/V(12.71b) * Rd(1.10%) * (1-Tc(0.20)))
Discount Rate = 8.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.78%
[DCF Debug] Terminal Value 76.04% ; FCFE base≈405.6m ; Y1≈353.7m ; Y5≈285.5m
Fair Price DCF = 43.95 (DCF Value 5.17b / Shares Outstanding 117.7m; 5y FCF grow -15.64% → 3.0% )
EPS Correlation: -38.09 | EPS CAGR: -48.26% | SUE: -4.0 | # QB: 0
Revenue Correlation: 17.92 | Revenue CAGR: 0.07% | SUE: 1.54 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.27 | Chg30d=+0.001 | Revisions Net=+2 | Analysts=10
EPS next Year (2026-12-31): EPS=5.28 | Chg30d=+0.005 | Revisions Net=+9 | Growth EPS=+7.6% | Growth Revenue=+3.3%

Additional Sources for HSIC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle